Table 4.
Wnt signaling is significantly altered upon GC effect in all experiments.
| GC Target Tissue Type’s Gene Expression | # of DEGs (p < 0.05) | Ratio of WNT Pathway Members * | # of Affected BP | # of Affected BP Related to WNT Signaling ** |
|---|---|---|---|---|
| Human bone tissue biopsies from CS patients, before vs. 3 months after surgery [53] | 1423 | 14/151 | 312 | 4 |
| Human primary osteoblast cell control vs. dex [54] | 5343 | 52/151 | 1573 | 11 |
| Human primary osteoblast-like cells (HObs) from bone explant control vs. dex [55] | 7279 | 53/151 | 1164 | 6 |
| Human primary synovial fibroblasts control or dex [56] | 10 | 8/151 | 880 | 41 |
| Human primary abdominal subcutaneous adipose cells control vs. dex [57] | 4276 | 37/151 | 2644 | 16 |
| Human primary abdominal omental adipose cells control vs. dex [57] | 3787 | 32/151 | 2422 | 6 |
| Human primary epidermal keratinocytes control vs. dex [58] | 1130 | 13/151 | 1753 | 7 |
| Piglet hippocampus tissue control vs. im. dex treated [59] | 2403 | 34/151 | 1913 | 10 |
| Piglet hypothalamus tissue control vs. im. dex treated [59] | 2661 | 33/151 | 1850 | 11 |
*: ratio of WNT pathway members: differentially expressed gene in Wnt signaling/all members (151 genes) of Wnt pathway according to KEGG gene set (hsa04310); **: detailed BP categories are listed in Table S2; #: The number of DEGs; BP: biological process (gene ontology category); DEGs: differentially expressed genes, dex: dexamethasone; CS: Cushing’s syndrome.